Condition: Hay Fever
Interventions: Biological: Placebo solution; Biological: gpASIT+TM
Sponsor: BioTech Tools S.A.
Not yet recruiting – verified September 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Condition: Hay Fever
Interventions: Biological: Placebo solution; Biological: gpASIT+TM
Sponsor: BioTech Tools S.A.
Not yet recruiting – verified September 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Allergy immunotherapy prevents asthma in patients with allergic rhinitis
Healio “Allergy immunotherapy effectively prevents the progression of allergic rhinitis to asthma in a real-life setting. This asthma-preventive effect is strongest in products containing native allergens,” Jochen Schmitt, MD, MPH, of the Center for Evidence … |
View full post on asthma – Google News
Sublingual Immunotherapy Not Currently Recommended For Asthma Control
Medical Research News and Interviews on MedicalResearch.com (blog) Response: Asthma is a common, long-term, respiratory condition which affects over 300 million people worldwide. It is a burden not only for the individual with asthma but also for the health services that care for them and the wider economy, due to … |
View full post on asthma – Google News
Conditions: Asthma; Perennial Allergic Rhinitis,
Intervention: Biological: Mouse Allergenic Extract
Sponsors: National Institute of Allergy and Infectious Diseases (NIAID); Inner-City Asthma Consortium
Recruiting – verified August 2015
View full post on ClinicalTrials.gov: asthma | received in the last 14 days
Hanford Sentinel |
Asthma, allergies and the new hope of immunotherapy
Hanford Sentinel The Asthma and Allergy Foundation of America has produced a list of the Spring Allergy Capitals of 2015, naming the cities expected to be hardest on allergy/asthma sufferers. The list is based on data such as levels of pollen and mold, plus … |
View full post on asthma – Google News
Pocono Record |
Asthma, allergies and the new hope of immunotherapy
Pocono Record When Lori Feeney's 7-year-old daughter, Allison, suffered a minor asthma attack while playing soccer, the mother knew her attempts at managing her daughter's seasonal allergies weren't working. In fact, she didn't even know her daughter had asthma. |
View full post on asthma – Google News
Chicago Tribune |
Asthma, allergies and the new hope of immunotherapy
Chicago Tribune When Lori Feeney's 7-year-old daughter, Allison, suffered a minor asthma attack while playing soccer, the mother knew her attempts at managing her daughter's seasonal allergies weren't working. In fact, she didn't even know her daughter had asthma. PURE Solutions Partners with Allergy and Asthma Network to Provide Allergy … Food allergy nation A season for allergies: Q&A with Dr. Tao Zheng |
View full post on asthma – Google News
Related Articles |
A major step forward for sublingual immunotherapy: the quality of 5-grass pollen tablet is recognized also in Italy.
J Asthma Allergy. 2015;8:25-7
Authors: Ciprandi G
PMID: 25834457 [PubMed]
View full post on pubmed: asthma
Sublingual immunotherapy tablet safe in asthma patients
Medical Xpress (HealthDay)—For individuals with asthma and allergic rhinitis with/without conjunctivitis (AR/C), treatment with a Timothy grass sublingual immunotherapy tablet (SLIT-tablet) seems safe, according to research published online Dec. 14 in Allergy. |
View full post on asthma – Google News
IL-10 and Regulatory T Cells Cooperate in Allergen-Specific Immunotherapy To Ameliorate Allergic Asthma.
J Immunol. 2014 Dec 19;
Authors: Böhm L, Maxeiner J, Meyer-Martin H, Reuter S, Finotto S, Klein M, Schild H, Schmitt E, Bopp T, Taube C
Abstract
Human studies demonstrated that allergen-specific immunotherapy (IT) represents an effective treatment for allergic diseases. IT involves repeated administration of the sensitizing allergen, indicating a crucial contribution of T cells to its medicinal benefit. However, the underlying mechanisms of IT, especially in a chronic disease, are far from being definitive. In the current study, we sought to elucidate the suppressive mechanisms of IT in a mouse model of chronic allergic asthma. OVA-sensitized mice were challenged with OVA or PBS for 4 wk. After development of chronic airway inflammation, mice received OVA-specific IT or placebo alternately to airway challenge for 3 wk. To analyze the T cell-mediated mechanisms underlying IT in vivo, we elaborated the role of T-bet-expressing Th1 cells, T cell-derived IL-10, and Ag-specific thymic as well as peripherally induced Foxp3(+) regulatory T (Treg) cells. IT ameliorated airway hyperresponsiveness and airway inflammation in a chronic asthma model. Of note, IT even resulted in a regression of structural changes in the airways following chronic inhaled allergen exposure. Concomitantly, IT induced Th1 cells, Foxp3(+), and IL-10-producing Treg cells. Detailed analyses revealed that thymic Treg cells crucially contribute to the effectiveness of IT by promoting IL-10 production in Foxp3-negative T cells. Together with the peripherally induced Ag-specific Foxp3(+) Treg cells, thymic Foxp3(+) Treg cells orchestrate the curative mechanisms of IT. Taken together, we demonstrate that IT is effective in a chronic allergic disease and dependent on IL-10 and thymic as well as peripherally induced Ag-specific Treg cells.
PMID: 25527785 [PubMed – as supplied by publisher]
View full post on pubmed: asthma